Introduction {#Sec1}
============

Primary cells cultured from ex vivo isolated tissues originating from different spatial sources of the same organism may show specific phenotypes, including distinct fingerprints of cellular metabolism (Pearson [@CR26]). One way to monitor cellular metabolism is through multiplexed cell energetics assays. A new approach explored in this study was to use Biolog Phenotype MicroArray™ technology to characterize cells for metabolically and bioenergetically-linked phenotypes (Bochner et al. [@CR2]; Putluri et al. [@CR27]). By simultaneously measuring utilization of hundreds of substrates, this assay system can reveal unique and insightful information on metabolic pathway activities and cellular responses to nutrients, hormones, cytokines, ions, and anti-cancer agents.

Systemic sclerosis (SSc) or scleroderma is a chronic, multiorgan autoimmune disease complicated by early vasculopathy and heart involvement (Boueiz et al. [@CR3]; Hettema et al. [@CR11]; Meune et al. [@CR20]; Ngian et al. [@CR23]) as well as progressive fibrosis of the skin and internal organs, including lungs (Kuwana et al. [@CR15]; Reiseter et al. [@CR28]). Thus, endothelial cells and fibroblasts are among the earliest and most affected cell types in SSc. The endothelium is heterogeneous depending on its vascular bed and tissue/embryological origin. Different endothelial cell phenotypes exhibit differential responses to changes in their environment and signaling (Rosenberg and Aird [@CR30]). Thus, human endothelial cells derived from the umbilical vein (HUVEC) have a specific and intrinsic expression pattern of inflammatory molecules as compared to human coronary artery endothelial cells (HCAEC). Cardiovascular cells that contribute directly to atherosclerosis and cardiac dysfunction are known to exhibit metabolic flexibility, characterized by the ability to switch from generating ATP primarily through oxidative phosphorylation to using glycolysis as the predominant energy source, as well as to shift from one fuel source to another (Vallerie and Bornfeldt [@CR35]). This flexibility occurs in endothelial cells, myeloid cells, and cardiomyocytes during normal development and physiology, and is thought to have evolved to protect cells with heightened energy demand from the increased oxidative stress that can be a result of elevated rates of oxidative phosphorylation (Galvan-Pena and O'Neill [@CR9]). The cells shunt glucose to oxidative side branches of glycolysis (Eelen et al. [@CR7]), to provide energy more rapidly (Galvan-Pena and O'Neill [@CR9]), or to use the most abundant fuel available (Kolwicz et al. [@CR13]). Studies support the concept that metabolic flexibility confers the advantage of ensuring ATP supplies for continual cardiac contraction under a variety of physiological conditions (Goodwin and Taegtmeyer [@CR10]; Kaijser and Berglund [@CR12]; Schonekess [@CR31]; Wentz et al. [@CR37]).

Cardiac metabolism also undergoes a reprogramming in response to pathological hypertrophy, characterized by increased reliance on glucose metabolism and decreased fatty acid oxidation (Kolwicz et al. [@CR13]). The question then arises whether metabolic flexibility and dysfunction in vascular and cardiac cells themselves could contribute to cardiovascular pathologies. Since patients with SSc have an elevated risk for vasculopathy, our aim was to determine what kind of metabolism HCAEC exhibit in comparison to a standardly used, however less appropriate, HUVEC model.

In the past, we have shown that HCAEC have a higher responsiveness and susceptibility to cytokines, and can as such, represent an excellent gene and protein expression model for evaluating the effects of vascular stress (Lakota et al. [@CR16], [@CR17], [@CR18]). Therefore, it is of interest whether HCAEC have a different metabolic phenotype at baseline levels than HUVEC.

SSc is also a complex chronic connective tissue disease characterized by progressive fibrosis (Laar and Varga [@CR36]) which can lead to irreversible damage of external and internal organs, such as the skin and lungs, respectively. The major cells implicated in fibrosis are fibroblasts, with their main physiological function in wound healing and tissue remodeling. The fibrotic component is dominant in SSc, as compared to other autoimmune diseases and determines its prognosis and therapeutic refractoriness. Studies in cultured SSc skin fibroblasts have facilitated the identification of potential pathways involved in their profibrotic phenotype. Profibrotic fibroblasts characterized by abnormal growth and extracellular matrix synthesis may differentiate or expand from normal resident fibroblasts and multiple factors, including signaling pathways appear to be involved in the development and/or persistence of the SSc fibroblast phenotype (Usategui et al. [@CR34]). We postulate that fibroblasts, when activated/stimulated, under stress microenvironment conditions, could function much like cancer cells, with unbridled proliferation, due to a redirection of their metabolism by the reverse Warburg effect (Pavlides et al. [@CR24]). In cancer, fibroblasts/stromal cells can convert to myofibroblasts, which (using glycolysis) can produce large amounts of lactate and pyruvate, thus feeding the faster growing cancer cells (Pavlides et al. [@CR25]). It is interesting that in SSc, where fibroblasts are also highly activated and responsible for abnormal extracellular matrix accumulation (Usategui et al. [@CR34]), inhibition of autophagy and aerobic glycolysis was suggested as a primary strategy to reverse fibrosis (Castello-Cros et al. [@CR6]). Thus, studying metabolic utilization of substrates is relevant in disease development, as well as for providing innovative strategies to combat disease activity.

No data to our knowledge is currently available on the metabolic activity of human primary cell types using Biolog Phenotype MicroArray™ technology, and specifically fibroblast or endothelial cells utilizing multiple substrates. So, we aimed to measure metabolic activity of primary human endothelial and fibroblast cells on multiple carbon and energy sources, as well as determine their specific metabolic fingerprints using the Biolog Phenotype MicroArray™ and OmniLog assay system.

Materials and methods {#Sec2}
=====================

Cell culture {#Sec3}
------------

HCAEC, HUVEC and NHLF (normal human lung fibroblasts) are all primary cell types generated ex vivo from isolated tissue (Lonza, Inc. Basel, Switzerland). Cell characteristics as reported by the manufacturer are summarized in Supplementary Table 1. The cells were plated onto six well plates or 75  cm^2^ flasks (TPP, Trasadigen, Switzerland) at 37 °C in a humidified atmosphere with 5 % CO~2~. HCAEC were grown in EGM-2 M medium containing 5 % fetal bovine serum (FBS); for HUVEC we used EBM-2 medium containing 2 % fetal bovine serum (both from Lonza Inc., Basel, Switzerland). NHLF were cultivated in FGM-2 medium containing 2 % FBS. All media components were from Lonza Inc. (Basel, Switzerland). Prior to the experiments, cells were incubated in serum-free medium for 30 min.

Phenotype MicroArray and OmniLog optimization experiments {#Sec4}
---------------------------------------------------------

HCAEC and NHLF specifically, were used for optimization experiments. Optimal cell medium, reagent dye and seeding cell densities were tested. Two different cell media were also tested, specifically IF-M1 (with amino acids) and IF-M2 (without amino acids) with two different Redox Dye Mixes MA and MB using initially three different seeding densities. All Phenotype MicroArray assay components were from Biolog Inc. (Hayward, CA USA).

Specifically, cells were seeded into 96 well plates (TPP, Trasadigen, Switzerland) at seeding densities of 20.000, 10.000, 5.000, 2.500, 1.250 and 625 cells/well in a compete medium MC-0 (50 µL/well). The MC-0 medium was prepared using either IF-M1 or IF-M2 medium with added Pen/Strep, [l]{.smallcaps}-glutamine (0.3 mM) and dialyzed FBS (at final concentration 5 %) (all from Lonza Inc., Basel, Switzerland). Cells were then incubated for 1 h at 37 °C under 5 % CO~2~, before adding Biolog Redox Dye Mix MA (10 μL) or Biolog Redox Dye Mix MB (10 µL) and measuring tetrazolium reduction, resulting in formation of a purple colour.

Tetrazolium colorimetric measurements {#Sec5}
-------------------------------------

All cell types (HCAEC, HUVEC and NHLF) for experiments on Biolog Phenotype MicroArray plates PM-M1 to PM-M4 (Biolog Inc., Hayward, CA, USA) were used between passages 4 and 5. A total of 367 different carbon and energy substrates were tested, as shown in Table [1](#Tab1){ref-type="table"}. Cells were initially grown in 75 cm^2^ culture flasks to confluency, before they were resuspended at a density of 200.000 cells/ml in Biolog IF-M1 medium with Pen/Strep, [l]{.smallcaps}-glutamine and dialyzed-FBS. Cells were then washed 2× with PBS and detached with trypsin at 37 °C for 2 min. Trypsinization neutralizing solution was added and cells were centrifuged at 350×*g* for 5 min at room temperature. MC-0 assay medium was added and cell count determined on Countess cells counter (Thermo Fisher Scientific, USA). Additional MC-0 was added to achieve a cell density of 10.000 cells/50 µL, which was seeded into the plates and incubated at 37 °C under 5 % CO~2~ for 18 h. Following the incubation, 10 µL Redox Dye Mix MB/well was added, the plate covered with sealing tape to prevent CO~2~ loss and incubated at 37 °C in the OmniLog (Biolog Inc., Hayward, CA, USA) for 24 h to kinetically measure tetrazolium reduction. OmniLog measures the intensity of purple colour formation using a CCD camera to record digital images every 15 min. All experiments on PM-M1 to PM-M4 plates were done in triplicate (48 plates total).Table 1PM-M1 to PM-M4 substrate templates123456789101112PM-M1 MicroPlate™---carbon and energy sources A*Negative controlNegative controlNegative control*α-CyclodextrinDextrinGlycogenMaltitolMaltotriose[d]{.smallcaps}-Maltose[d]{.smallcaps}-Trehalose[d]{.smallcaps}-Cellobioseβ-Gentiobiose B*[d]{.smallcaps}* *-Glucose-6- phosphateα-* *[d]{.smallcaps}* *-Glucose-1-Phosphate*[l]{.smallcaps}-Glucose***α-*** ***[d-]{.smallcaps}*** ***Glucose**α-*** ***[d-]{.smallcaps}*** ***Glucose**α-*** ***[d-]{.smallcaps}*** ***Glucose***3-*O*-Methyl-[d]{.smallcaps}-glucoseα-Methyl-[d]{.smallcaps}-glucosideβ-Methyl-[d]{.smallcaps}- glucoside[d]{.smallcaps}-Salicin*[d]{.smallcaps}* *-Sorbitol*N-Acetyl-[d]{.smallcaps}- glucosamine C[d]{.smallcaps}-Glucosaminic acid*[d]{.smallcaps}* *-Glucuronic acid*Chondroitin-6-sulfate*Mannan[d-]{.smallcaps}* *Mannose*α-Methyl-[d]{.smallcaps}-mannoside[d]{.smallcaps}-Mannitol*N*-Acetyl-β-[d]{.smallcaps}- mannosamine[d]{.smallcaps}-MelezitoseSucrosePalatinose*[d]{.smallcaps}* *-Turanose* D*[d]{.smallcaps}* *-Tagatose*[l]{.smallcaps}-Sorbose[l]{.smallcaps}-Rhamnose[l]{.smallcaps}-Fucose[d]{.smallcaps}-Fucose*[d-]{.smallcaps}* *Fructose-6-Phosphate[d-]{.smallcaps}* *Fructose*Stachyose[d]{.smallcaps}-Raffinose[d]{.smallcaps}-LactitolLactuloseα-[d-]{.smallcaps}Lactose EMelibionic acid[d]{.smallcaps}-Melibiose*[d]{.smallcaps}* *-Galactose*α-Methyl-[d]{.smallcaps}-galactosideβ-Methyl-[d]{.smallcaps}-galactoside*N*-Acetyl-Neuraminic acid*Pectin*SedoheptulosanThymidine*UridineAdenosineInosine* FAdonitol[l]{.smallcaps}-Arabinose[d-]{.smallcaps}Arabinoseβ-Methyl-[d]{.smallcaps}-xylopyranoside*Xylitol*Myo-InositolMeso-ErythritolPropylene glycolEthanolamine*[d]{.smallcaps}*, *[l]{.smallcaps}* *-α-Glycerol-phosphate*GlycerolCitric acid G*Tricarballylic acid[d]{.smallcaps}*, *[l]{.smallcaps}* *-Lactic acid*Methyl [d]{.smallcaps}-lactateMethyl pyruvate*Pyruvic acidα-Keto-Glutaric acidSuccinamic acid*Succinic acid*Mono-methyl succinate*[l]{.smallcaps}-Malic acid[d]{.smallcaps}-Malic acidMeso-tartaric acid H*Acetoacetic acid (a)*γ-Amino-N-butyric acidα-Keto-buytric acid*α-Hydroxy-butyric acid*[d]{.smallcaps}, [l]{.smallcaps}-β-Hydroxy-butyric acidγ-Hydroxy-butyric acid*Butyric acid2,3-Butanediol*3-Hydroxy-2- Butanone*Propionic acidAcetic acidHexanoic acid*PM-M2 MicroPlate™---carbon and energy sources/nitrogen sources A*Negative controlNegative controlNegative control*Tween 20Tween 40Tween 80*Gelatin*[l]{.smallcaps}-Alaninamide[l]{.smallcaps}-Alanine[d-]{.smallcaps}Alanine[l]{.smallcaps}-Arginine[l]{.smallcaps}-Asparagine B[l]{.smallcaps}-Aspartic acid[d-]{.smallcaps}Aspartic acid*[l]{.smallcaps}* *-Glutamic acid[d-]{.smallcaps}* *Glutamic acid[l]{.smallcaps}* *-Glutamine*Glycine[l]{.smallcaps}-Histidine[l]{.smallcaps}-HomoserineHydroxy-L-Proline[l]{.smallcaps}-Isoleucine[l]{.smallcaps}-Leucine[l]{.smallcaps}-Lysine C[l]{.smallcaps}-Methionine[l]{.smallcaps}-Ornithine[l]{.smallcaps}-Phenylalanine[l]{.smallcaps}-Proline[l]{.smallcaps}-Serine[d-]{.smallcaps}Serine[l]{.smallcaps}-Threonine[d-]{.smallcaps}Threonine*[l]{.smallcaps}* *-Tryptophan*[l]{.smallcaps}-Tyrosine[l]{.smallcaps}-ValineAla-Ala DAla-ArgAla-AsnAla-Asp*Ala-GluAla-Gln*Ala-GlyAla-HisAla-IleAla-LeuAla-LysAla-MetAla-Phe EAla-ProAla-SerAla-ThrAla-TrpAla-TyrAla-ValArg-Ala (b)Arg-Arg (b)Arg-Asp*Arg-Gln*Arg-GluArg-Ile (b) FArg-Leu (b)Arg-Lys (b)Arg-Met (b)*Arg-Phe (b)*Arg-Ser (b)Arg-TrpArg-Tyr (b)Arg-Val (b)Asn-GluAsn-ValAsp-AlaAsp-Asp GAsp-Glu*Asp-Gln*Asp-GlyAsp-LeuAsp-LysAsp-PheAsp-TrpAsp-ValGlu-AlaGlu-AspGlu-GluGlu-Gly HGlu-Ser*Glu-TrpGlu-Tyr*Glu-Val*Gln-GluGln-GlnGln-Gly*Gly-AlaGly-ArgGly-AsnGly-Asp***α-*** *[D-]{.smallcaps}* ***Glucose***PM-M3 MicroPlate™---carbon and energy sources/nitrogen sources A*Negative controlNegative controlNegative control*Gly-Gly*Gly-HisGly-Ile*Gly-Leu*Gly-LysGly-MetGly-Phe*Gly-Pro*Gly-Ser* BGly-ThrGly-TrpGly-TyrGly-ValHis-AlaHis-Asp*His-Glu*His-GlyHis-His (c)His-LeuHis-Lys (d)His-Met C*His-Pro*His-Ser*His-Trp*His-TyrHis-ValIle-AlaIle-Arg (b)Ile-Asn*Ile-Gln*Ile-GlyIle-HisIle-Ile D*Ile-Leu*Ile-MetIle-PheIle-ProIle-Ser*Ile-Trp*Ile-TyrIle-ValLeu-AlaLeu-Arg (b)Leu-AsnLeu-Asp E*Leu-Glu*Leu-GlyLeu-HisLeu-IleLeu-LeuLeu-MetLeu-PheLeu-ProLeu-Ser*Leu-Trp*Leu-TyrLeu-Val FLys-Ala (d)Lys-Arg (b)Lys-AspLys-GluLys-GlyLys-Ile (b)*Lys-Leu (b)*Lys-LysLys-Met (e)Lys-PheLys-ProLys-Ser GLys-Thr*Lys-Trp (b)Lys-Tyr (b)*Lys-Val (d)Met-Arg (b)Met-Asp*Met-Gln*Met-GluMet-GlyMet-HisMet-Ile*Met-Leu* H*Met-Lys (e)Met-MetMet-PheMet-ProMet-ThrMet-TrpMet-TyrMet-ValPhe-AlaPhe-AspPhe-Glu****α-*** *[d-]{.smallcaps}* ***Glucose***PM-M4 MicroPlate™---carbon and energy sources/nitrogen sources A*Negative controlNegative controlNegative control*Phe-GlyPhe-Ile*Phe-MetPhe-Phe*Phe-ProPhe-Ser*Phe-TrpPhe-TyrPhe-Val* BPro-Ala*Pro-Arg (b)*Pro-AsnPro-Asp*Pro-GluPro-Gln*Pro-GlyPro-HypPro-IlePro-LeuPro-Lys (b)Pro-Phe CPro-ProPro-Ser*Pro-Trp*Pro-TyrPro-ValSer-Ala*Ser-Asn*Ser-AspSer-Glu*Ser-Gln*Ser-GlySer-His(b) DSer-LeuSer-MetSer-PheSer-ProSer-SerSer-TyrSer-ValThr-AlaThr-Arg (f)Thr-AspThr-Glu*Thr-Gln* EThr-GlyThr-LeuThr-MetThr-PheThr-ProThr-Ser*Trp-Ala*Trp-ArgTrp-Asp*Trp-Glu*Trp-GlyTrp-Leu FTrp-Lys (e)Trp-PheTrp-Ser*Trp-TrpTrp-TyrTrp-Val*Tyr-Ala*Tyr-GlnTyr-Glu*Tyr-GlyTyr-HisTyr-Ile GTyr-LeuTyr-LysTyr-PheTyr-TrpTyr-TyrTyr-ValVal-AlaVal-ArgVal-AsnVal-AspVal-Glu*Val-Gln* HVal-GlyVal-HisVal-IleVal-LeuVal-LysVal-Met*Val-PheVal-Pro*Val-SerVal-Tyr*Val-Val****α-*** *[d-]{.smallcaps}* ***Glucose***367 biochemical substrates on PM-M1, PM-M2, PM-M3 and PM-M4 microplates are indicated. PM-M1 contains primarily carbohydrate and carboxylic substrates, while PM-M2, PM-M3 and PM-M4 contain individual L-amino acids and most dipeptide combinations (Biolog Inc.). The highlighted areas indicate substrates that were utilized by all three, or any one or two cell types HCAEC, HUVEC and NHLFAcidic substances are sodium salts and basic substances are the chloride salts, except as noted (a): lithium salt, (b): acetate salt, (c): trifluoroacetate salt, (d): bromide salt, (e): formate salt, (f): sulfate salt

Statistical analysis {#Sec6}
--------------------

The Omnilog PMM Data Analyses Software was used to analyze metabolic phenotypes. The data were adjusted by subtracting average values of three negative control wells from all other samples at the end time point. Metabolic responses were normalized due to the differences in doubling times of the different cell types. Omnilog data exportable parameters were exported to Microsoft Excel and Bar graphs were made. Venn diagrams and digital images were processed using CorelDraw.

Results and discussion {#Sec7}
======================

Primary human cell types and growth conditions {#Sec8}
----------------------------------------------

In order to investigate cell morphology and growth of human primary endothelial (HCAEC, HUVEC), as well as fibroblast (NHLF) cells, inverted microscopy was used. Cells appeared phenotypically healthy, with endothelial cells exhibiting "cobblestone" morphology, while fibroblasts appeared typically elongated (Fig. [1](#Fig1){ref-type="fig"}). For measurement of the cellular metabolism Biolog Phenotype MicroArray was used. The kinetics of purple formazan accumulation was measured with OmniLog PMM System, operating as an incubator/reader that holds up to 50 microplates, and reads/quantifies colour density in each well, every 15 min over the user-specified time period. Prior to all measurements of cell metabolic activity, it is useful to first optimize which of the two dye mixes will work better for the cell type under study and how many cells will be needed per well to produce a given amount of reduced formazan product within an appropriate time frame. Dye preference and optimal number of cells for determining growth in complete medium has previously been determined for 15 different human, mouse and rat cell lines ([http://biolog.com/pdf/pmmlit/00P%20133rC%20Redox%20Dye%20Mix%20Brochure%20JUL07.pdf](http://biolog.com/pdf/pmmlit/00P%2520133rC%2520Redox%2520Dye%2520Mix%2520Brochure%2520JUL07.pdf)), however no data is currently available on optimal conditions for primary human endothelial and fibroblast cells. We therefore performed experiments which determined the specific media (M1 or M2), cell densities and Biolog redox dye mixes (MA or MB) to be used (Fig. [2](#Fig2){ref-type="fig"}). No reaction was detected using Biolog Redox Dye Mix MA. M1 medium enabled slightly stronger reactions compared to M2 medium. The cell density of 10.000 cells/well was the first dilution to give maximal readings while 5.000 cells/well showed considerably decreased responses. The optimal conditions for growth of HCAEC and NHLF were therefore set on 10.000 cells/well in Biolog IF-M1 medium with 1 × Pen/Strep, 0.3 mM [l]{.smallcaps}-glutamine and 5 % dialysed FBS with Biolog Redox Dye Mix MB (10 µl/well) (Fig. [2](#Fig2){ref-type="fig"}). These conditions were used in all subsequent experiments determining cell growth on different substrates.Fig. 1Different phenotypes of human primary endothelial and fibroblast cells. Micrographs show normal, healthy endothelial cells isolated from coronary arteries, umbilical vein and fibroblasts from the lungs. *HCAEC* human coronary artery endothelial cells, *HUVEC* human umbilical vein endothelial cells and *NHLF* normal human lung fibroblastsFig. 2Optimization of Biolog media, redox dye mixes and cell density, for *HCAEC* human coronary artery endothelial cells and *NHLF* normal human lung fibroblasts. The OmniLog reading results, as area under *curve*, of the separate wells, are presented in *green*

Utilization of substrates on PM-M1, PM-M2, PM-M3 and PM-M4 microplates {#Sec9}
----------------------------------------------------------------------

The extent to which human primary cell types from various tissues use different carbon substrates for energy has, to our knowledge, not been systematically investigated. It is known that, in addition to glucose, animal cells can metabolize and grow on other substrates (Bochner et al. [@CR2]). In 1976, a survey of nutrient metabolism (Burns et al. [@CR5]) examined 93 carbohydrates of which (a) 15 supported mammalian cell proliferation and (b) 42 were toxic or growth inhibitory and concluded that carbohydrate preferences of cells can be utilized to biochemically distinguish between different mammalian cell lines. In the following years, culture media were developed using glucose, pyruvate, and glutamine as energy sources, which were shown to support growth of most cell types and the interest to investigate the diversity of possible nutrients metabolized by different cell types waned. Recently, there is renewed interest to understand how the metabolism of different cell types could contribute to pathological pathways and help develop new approaches in nutritional therapy to support and improve treatment of a wide range of systemic disorders.

Using the optimized assay conditions we measured metabolic utilization of different substrates by HCAEC, HUVEC and NHLF in four microplates PM-M1 to PM-M4 containing 367 substrate. Representative plates out of three independent experiments are shown (Fig. [3](#Fig3){ref-type="fig"}). Glucose is widely accepted as the primary nutrient for the maintenance and promotion of cell function and all cell types tested produced a strong response in wells containing glucose (Fig. [3](#Fig3){ref-type="fig"}, black boxes). Background, the average absorbance measured in negative controls, was subtracted from the data used for further analysis (Fig. [3](#Fig3){ref-type="fig"}, blue boxes). Exclusive substrates are indicated in HCAEC (Fig. [3](#Fig3){ref-type="fig"}, green boxes) and NHLF (yellow boxes), while HUVEC showed no exclusively utilized substrates.Fig. 3HCAEC, HUVEC and NHLF assayed in PM-M1 to PM-M4. The *columns* show the endpoint of a 24 h incubation of a representative replicate of three independent experiments performed. Positive wells with glucose utilization are indicated with *black boxes*, while negative, background wells are shown with *blue boxes*. Exclusive results obtained for HCAEC are shown in *green boxes* and for NHLF in *yellow boxes*. *HCAEC* human coronary artery endothelial cells, *HUVEC* human umbilical vein endothelial cells and *NHLF* normal human lung fibroblasts

Data analysis of substrate utilization {#Sec10}
--------------------------------------

All three cell types highly utilized adenosine, inosine, [d]{.smallcaps}-mannose and dextrin as substrates (to tetrazolium reduction levels above 100 mOD), comparable to glucose. Using plates PM-M1 through PM-M4, patterns of substrate utilization were observed for HCAEC, HUVEC and NHLF, as indicated in green, red and yellow bars, respectively (Fig. [4](#Fig4){ref-type="fig"}). HCAEC (green bars), prevalently utilized substrates on PM-M1 and to a lesser extent on PM-M3, with only a few substrates utilized on PM-M2 and PM-M4. NHLF, on the other hand, showed high and exclusive utilization of certain glutamine-associated peptides on PM-M2, PM-M3 and PM-M4, not observed in either HCAEC or HUVEC (Figs. [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}).Fig. 4Comparison of substrate utilization in all three cell types are shown on plates PM-M1 and PM-M2, PM-M3 and PM-M4. Cells were assayed according to the standard protocol and data collected after 24 h using the OmniLog and PM software, with subtraction of the background. Average height (mOD) of tetrazolium reduction was measured in triplicate. *HCAEC* human coronary artery endothelial cells, *HUVEC* human umbilical vein endothelial cells and *NHLF* normal human lung fibroblasts

HCAEC were able to use a larger number of substrate nutrients, with higher tetrazolium reduction, as measured in mOD for energy production than HUVEC (such as dextrin, glycogen, maltotriose, [d]{.smallcaps}-maltose, α-[d]{.smallcaps}-glucose-6-phosphate, mannan, [d]{.smallcaps}-mannose, [d]{.smallcaps}-turanose, [d]{.smallcaps}-fructose-6-phosphate, [d]{.smallcaps}-galactose, pectin, uridine, adenosine, inosine, [d]{.smallcaps}, [l]{.smallcaps}-α-glycerol-phosphate, tricarballylic acid, [d]{.smallcaps}, [l]{.smallcaps}-lactic acid, pyruvic acid, α-keto-glutaric acid, succinamic acid, among others) (Fig. [4](#Fig4){ref-type="fig"}). The specific substrates metabolized only by HCAEC, and not by either HUVEC or NHLF were the polymeric substrates mannan, pectin, gelatin, Val-Val and prevalently tricarballylic acid, as shown in Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}. HUVEC did not show any exclusive metabolism of any substrates, but it was differentiated from HCAEC by notably stronger metabolism of D-glucuronic acid.

The assays indicate that cardiovascular cells, such as HCAEC exhibit extensive metabolic flexibility enabling them to produce energy more rapidly and use the most abundant fuel available, as well. These characteristics might also contribute directly to atherosclerosis and cardiac dysfunction, which are both known to be associated with changes in metabolism and obesity.

NHLF produced saturation of tetrazolium reduction in glucose wells during the 24 h kinetic measurements and utilized many substrates. Specifically, dextrin, glycogen, maltotriose, [d]{.smallcaps}-maltose, [d]{.smallcaps}-mannose, [d]{.smallcaps}-fructose-6-phosphate, inosine, [d]{.smallcaps}, [l]{.smallcaps}-lactic acid, [d]{.smallcaps}-glucose-6-phosphate, α-[d]{.smallcaps}-glucose-6-phosphate and adenosine produced strong reductive responses. Strikingly, NHLF also showed higher metabolism of the polyols [d]{.smallcaps}-sorbitol and xylitol along with [l]{.smallcaps}-glutamic acid, [l]{.smallcaps}-glutamine and all of the glutamine-containing dipeptides (Fig. [4](#Fig4){ref-type="fig"}, PM-M2, PM-M3 and PM-M4, yellow bars).

The most relevant glutamine-producing tissue is the muscle, accounting for about 90 % of all glutamine synthesized (Newsholme et al. [@CR22]). Glutamine is also released, in small amounts, by the lung and the brain. In contrast, the biggest consumers of glutamine are the cells of intestines (Brosnan [@CR4]), the kidney cells for the acid--base balance, activated immune cells (Newsholme [@CR21]), and many cancer cells (Yuneva et al. [@CR38]). We show for the first time, that normal healthy primary lung fibroblasts (in contrast to either HCAEC or HUVEC) have higher utilization of glutamine and glutamine-associated dipeptides. Glutamine has been shown in the past to be essential for growth of human embryonic diploid lung fibroblasts, when 10 % undialysed calf serum was used as a medium supplement (Litwin [@CR19]). Interstitial fibroblasts within a biomatrix are exposed to varying levels of amino acids (Rishikof et al. [@CR29]) and it was previously found that expression of α1(I) collagen mRNA was directly dependent on amino acid availability (Krupsky et al. [@CR14]). Since type I collagen is a major structural protein in the lung known to participate in tissue fibrosis during systemic sclerosis, the effects of glutamine on its levels would be crucial to study. Rishikof et al. reported in 1998, on the regulation of type I collagen mRNA in human embryonic lung fibroblasts and found that the addition of the combination of glutamine and cysteine increased α1(I) collagen mRNA levels 6.3-fold (Rishikof et al. [@CR29]). Importantly, glutamine, utilized for nucleotide synthesis (Engstrom and Zetterberg [@CR8]) also increased α1(I) collagen mRNA in dermal fibroblasts by elevating gene transcription (Bellon et al. [@CR1]).

The tetrazolium reduction measured in [l]{.smallcaps}-tryptophan during the 24 h measurements was detected in low levels only in NHLF. Neither HCAEC nor HUVEC metabolized [l]{.smallcaps}-tryptophan during this time frame. It is of interest that the metabolism of [l]{.smallcaps}-tryptophan is involved, via the kynurenine pathway, in patients with the eosinophilia-myalgia syndrome (Silver et al. [@CR33]). Ingesting tryptophan may lead to a syndrome characterized by scleroderma-like skin abnormalities, fasciitis, in addition to eosinophilia. Plasma concentrations of [l]{.smallcaps}-kynurenine and quinolinic acid, both metabolites of tryptophan, were significantly higher in patients with active disease, as compared to patients studied after eosinophilia had resolved, or normal subjects (Silver et al. [@CR32]). Since in late, diffused scleroderma, lungs can be prevalently affected, it could be hypothesized that this could be due to changed metabolism of tryptophan pathways in lung fibroblasts from patients. This would be relevant to test in the future.

Comparison of exclusive and overlapping substrates {#Sec11}
--------------------------------------------------

Comparison of all three cell types together revealed that 49 of the 367 tested substrates were utilized by all three cell types, however both HCAEC and NHLF utilized several substrates uniquely, with a distinct pattern. On the other hand, HUVEC did not exhibit any exclusively utilized substrates. The specific substrates metabolized only by HCAEC, and not by HUVEC or NHLF were mannan, pectin, gelatin, Val-Val and prevalently tricarballylic acid, as shown in the Venn diagram (Fig. [5](#Fig5){ref-type="fig"}). NHLF were the only cells utilizing [d]{.smallcaps}-sorbitol, xylitol, [l]{.smallcaps}-glutamic acid, [d]{.smallcaps}-glutamic acid, [l]{.smallcaps}-tryptophan and the dipeptides Ala-Glu, Arg-Gln, Arg-Phe (b), Asp-Gln, Asp-Trp,Ile-Trp, Leu-Trp, Phe-Gly, Pro-Arg (b), Pro-Glu, Pro-Gln, Pro-Trp, Trp-Ala and Trp-Glu for their energy production (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Unique substrates metabolized exclusively by HCAEC, HUVEC and NHLF, as well as overlapping substrates, are represented by the Venn diagram. *HCAEC* human coronary artery endothelial cells, *HUVEC* human umbilical vein endothelial cells and *NHLF* normal human lung fibroblasts

Metabolism of substrates was measured within a 24 h timeframe. In the future, it could be advantageous to measure metabolic activity of different human primary cell lots, passages and preparations at different time periods with altered CO~2~ and oxygen levels in the incubator. This could be especially important for utilization of certain substrates, such as [l]{.smallcaps}-Glutamine, [l]{.smallcaps}-Tryptophan, Met- and Val- associated dipeptides, which indicated firm delineation between the fibroblast and endothelial cells.

Our results confirm that human primary cells can exhibit a unique and distinct metabolic fingerprint which could make them differentially susceptible to environmental changes that could subsequently lead to differential pathological processes.

Concluding remarks {#Sec12}
==================

Taken together, this is the first report to date exhibiting specific utilization of different carbon and energy sources of human primary endothelial and fibroblast cells on Biolog PM-M1 to PM-M4 plates. We showed that HCAEC have a higher overall metabolic rate than HUVEC, and that mannan, pectin, gelatin, Val-Val and prevalently tricarballylic acid were utilized exclusively by HCAEC. NHLF exhibited high metabolic activity by utilizing many substrate nutrients for energy production, especially glutamine associated dipeptides (Ala-Gln, Arg-Gln, Asp-Gln, Gln-Gly, Gln-Gln, Gln-Glu, Ile-Gln, Met-Gln, Pro-Gln, Ser-Gln, Thr-GlnTyr-Gln and Val-Gln). Also, the lack of utilization of mannan, pectin and gelatin in NHLF, coupled with their unique utilization of [d]{.smallcaps}-sorbitol, xylitol, [l]{.smallcaps}-tryptophan and tryptophan-associated dipeptides (Asp-Trp, Ile-Trp, Leu-Trp, Pro-Trp, Trp-Ala and Trp-Glu) points to a distinct lung fibroblast metabolic phenotype. Taken together, substrate utilization patterns on PM-M1 to PM-M4 plates provide a baseline metabolic characterization of different human primary cell types, which could be important in distinguishing early and cell-type specific metabolic changes that could initiate pathophysiological processes. In the future, it would be crucial to perform further experiments on activated cells or cells isolated from patient tissues, in order to elucidate early cellular changes relevant to cardiac complications, as well as the process of lung fibrosis in systemic sclerosis.
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